KPC Pharmaceuticals

KPC Pharmaceuticals EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 42.38. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 9.26 — a change of 357.57% (higher).

EV/FCF

42.38

YoY

357.57%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of KPC Pharmaceuticals is 2025 42.38 . EV/FCF (Enterprise Value to Free Cash Flow) of KPC Pharmaceuticals was 2024 9.26 . It decreases by 357.57% higher compared to the previous year.

The KPC Pharmaceuticals EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
60.40 CNY
Jan 1, 2019
94.67 CNY
Jan 1, 2020
30.15 CNY
Jan 1, 2021
501.19 CNY
Jan 1, 2022
51.36 CNY
Jan 1, 2023
11.99 CNY
Jan 1, 2024
9.26 CNY
Jan 1, 2025
42.38 CNY
The KPC Pharmaceuticals EV/FCF history
YEAREV/FCFYoY
42.38+357.57%
9.26-22.72%
11.99-76.66%
51.36-89.75%
501.19+1,562.60%
30.15-68.16%
94.67+56.73%
60.40-118.60%
-324.69-520.60%
77.20+144.68%
31.55-40.03%
52.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

EV/FCF (Enterprise Value to Free Cash Flow) of KPC Pharmaceuticals is 42.38 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of KPC Pharmaceuticals changed from 9.26 to 42.38, representing a 357.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s KPC Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals